This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n9http://localhost/temp/predkladatel/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F10%3A00002530%21RIV11-MSM-11120___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F10%3A00002530%21RIV11-MSM-11120___
rdf:type
skos:Concept n12:Vysledek
dcterms:description
The availability of anaphylaxis guidelines and of medications, supplies, and equipment for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings worldwide is unknown. Surveys were returned from 44 of 52 countries on 6 continents, for an 85% response rate. Anaphylaxis guidelines were reported to be in use in 70% of the 44 responding countries. The diagnosis of acute anaphylaxis was reported to be based on clinical history and physical examination alone in 63% of responding countries. Medications for anaphylaxis treatment were reported to be available in the 44 responding countries as follows: epinephrine (adrenaline) for injection, 100%; any intravenous glucocorticoid, 89%; any intravenous H1-antihistamine, 77%; any intravenous H2-antihistamine, 70%; glucagon, 73%; atropine, 73%; dopamine, 86%; noradrenaline, 70%; vasopressin, 64%; and a beta 2-agonist for nebulization, 86%. Supplies and equipment for anaphylaxis treatment were reported to be available i The availability of anaphylaxis guidelines and of medications, supplies, and equipment for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings worldwide is unknown. Surveys were returned from 44 of 52 countries on 6 continents, for an 85% response rate. Anaphylaxis guidelines were reported to be in use in 70% of the 44 responding countries. The diagnosis of acute anaphylaxis was reported to be based on clinical history and physical examination alone in 63% of responding countries. Medications for anaphylaxis treatment were reported to be available in the 44 responding countries as follows: epinephrine (adrenaline) for injection, 100%; any intravenous glucocorticoid, 89%; any intravenous H1-antihistamine, 77%; any intravenous H2-antihistamine, 70%; glucagon, 73%; atropine, 73%; dopamine, 86%; noradrenaline, 70%; vasopressin, 64%; and a beta 2-agonist for nebulization, 86%. Supplies and equipment for anaphylaxis treatment were reported to be available i
dcterms:title
World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings
skos:prefLabel
World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings
skos:notation
RIV/00216208:11120/10:00002530!RIV11-MSM-11120___
n3:aktivita
n17:V
n3:aktivity
V
n3:cisloPeriodika
5
n3:dodaniDat
n5:2011
n3:domaciTvurceVysledku
n16:9360344
n3:druhVysledku
n8:J
n3:duvernostUdaju
n4:S
n3:entitaPredkladatele
n13:predkladatel
n3:idSjednocenehoVysledku
298980
n3:idVysledku
RIV/00216208:11120/10:00002530
n3:jazykVysledku
n15:eng
n3:klicovaSlova
anaphylaxis; allergoogy; immunology; health care
n3:klicoveSlovo
n11:immunology n11:anaphylaxis n11:health%20care n11:allergoogy
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[87C65B5F4FCF]
n3:nazevZdroje
Annals of Allergy Asthma & Immunology
n3:obor
n14:EC
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
46
n3:rokUplatneniVysledku
n5:2010
n3:svazekPeriodika
104
n3:tvurceVysledku
Kučera, Petr
n3:wos
000285830100008
s:issn
1081-1206
s:numberOfPages
8
n9:organizacniJednotka
11120